LOGIN  |  REGISTER
C4 Therapeutics
Amneal Pharmaceuticals

Neogen Announces First-Quarter Earnings Release Date

September 18, 2025 | Last Trade: US$5.98 0.05 0.84

LANSING, Mich. / Sep 18, 2025 / Business Wire / Neogen® Corporation (NASDAQ: NEOG) will issue its first-quarter earnings release before the opening of the market on October 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results.

The conference call can be accessed by dialing:
Toll-Free - North America: 1-800-549-8228
International: (+1) 646-564-2877
Conference ID: 49915

The live webcast can be accessed through Neogen’s Investor Relations webpage, neogen.com/investor-relations, under the “Events & Presentations” subheading.

A replay of the conference call and webcast will be available shortly following the conclusion of the call and can be accessed by dialing:

Toll-Free - North America: 1-888-660-6264
International: (+1) 646 517 3975
Passcode: 49915 #

It will also be available on Neogen’s Investor Relations website at neogen.com/investor-relations.

About Neogen

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

C4 Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page